Me'ja Day, MD
Ophthalmology · Conyers, GANPI 1578978227
Payments from drug & device makers
Across 64 payments — averaging $24.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$235
- Alcon$228
- Glaukos Corporation$192
- Sun Pharmaceutical Industries Inc.$166
- Novartis$106
- Notal Vision, Inc.$92
- plus $568 from 20 others
What the payments were for
- Speaking & faculty fees$926%
- Food & beverage$1,49594%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 13 | $235 |
| Alcon | 10 | $228 |
| Glaukos Corporation | 1 | $192 |
| Sun Pharmaceutical Industries Inc. | 3 | $166 |
| Novartis | 6 | $106 |
| Notal Vision, Inc. | 2 | $92 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $73 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $69 |
| Bausch & Lomb Americas Inc. | 3 | $52 |
| Tarsus Pharmaceuticals, Inc. | 2 | $45 |
| NEW World Medical,inc. | 2 | $42 |
| Biotissue Holdings Inc. | 2 | $33 |
| Recordati_rare_diseases_inc. | 1 | $27 |
| Dompe US, Inc. | 1 | $26 |
| Thea Pharma Inc. | 1 | $23 |
| Sight Sciences, Inc. | 1 | $20 |
| ABB Con-cise Optical Group LLC | 1 | $19 |
| Eyepoint US, Inc. | 1 | $19 |
| Shire North American Group Inc | 1 | $17 |
| Aerie Pharmaceuticals, Inc. | 1 | $17 |
| AbbVie | 1 | $16 |
| Merz Pharmaceuticals, LLC | 1 | $15 |
| Kala Pharmaceuticals, Inc. | 1 | $15 |
| Oyster Point Pharma, Inc. | 1 | $14 |
| Akorn Operating Company LLC | 1 | $14 |
| Rxsight Inc | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CEQUA$114
How this compares
$1,587 in reported general payments places this provider in the 40th percentile of 481 ophthalmology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 39 | $37,568 |
| LumiganBimatoprost | 58 | $23,541 |
| XiidraLifitegrast | 19 | $19,437 |
| CombiganBrimonidine Tartrate/Timolol | 31 | $9,910 |
| TyrvayaVarenicline Tartrate | 15 | $9,325 |
| VyzultaLatanoprostene Bunod | 29 | $8,723 |
| Travoprost | 59 | $5,368 |
| Latanoprost | 418 | $2,985 |
| Cyclosporine | 11 | $2,759 |
| Prednisolone Acetate | 60 | $2,668 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 22 | $2,379 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 118 | $2,074 |
| Dorzolamide Hcl | 69 | $1,321 |
| Azelastine Hcl | 40 | $1,023 |
| Brimonidine Tartrate | 111 | $936 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $16 | $71,020128 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $52 | $28,16048 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $14 | $9,32515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 481 ophthalmology providers in Georgia.
Other ophthalmology in Conyers
- Yogin PatelConyers$34K
- Dennis MarcusAugusta$9.2M
- Robert StoltzMarietta$3.9M
- Eugene McLaurinSavannah$3.3M
- Clayton BlehmGainesville$1.7M
- Lakshmana KooragayalaMarietta$1.4M
- Douglas DayAtlanta$1.1M
- Jennifer KimMorrow$989K
- Thomas AabergAtlanta$959K
- Gagan SawhneyAtlanta$874K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.